Samsung Life Insurance Co., Ltd. (KRX:032830)
South Korea
· Delayed Price · Currency is KRW | Market Cap | 45.25T |
| Revenue (ttm) | 20.00T |
| Net Income (ttm) | 2.30T |
| Shares Out | 179.57M |
| EPS (ttm) | 12,823.83 |
| PE Ratio | 19.65 |
| Forward PE | 18.38 |
| Dividend | 5,300.00 (2.12%) |
| Ex-Dividend Date | Dec 29, 2025 |
| Volume | 317,520 |
| Average Volume | 298,146 |
| Open | 248,000 |
| Previous Close | 250,000 |
| Day's Range | 246,500 - 255,000 |
| 52-Week Range | 82,600 - 262,500 |
| Beta | 0.73 |
| RSI | 57.92 |
| Earnings Date | May 14, 2026 |
About Samsung Life Insurance
Samsung Life Insurance Co., Ltd., together with its subsidiaries, engages in the life insurance business to corporate and individual customers in South Korea and internationally. The company operates through Domestic Insurance; Credit Card Service, Installment Financing and Leasing; and Overseas segments. It also offers various loan products for companies, household, and stocks and bonds, as well as mortgage loans; and retirement pension, funds, and asset management services. The company was formerly known as Dongbang Life Insurance and changed... [Read more]
Financial Performance
In 2025, Samsung Life Insurance's revenue was 34.84 trillion, an increase of 21.45% compared to the previous year's 28.69 trillion. Earnings were 2.30 trillion, an increase of 9.30%.
Financial StatementsNews
Samsung Life Insurance Earnings Call Transcript: Q4 2025
Net profit for FY2025 rose 9.3% to KRW 2.3 trillion, with record CSM growth and strong health product sales. Dividend per share increased 18%, and the company targets further CSM and DPS growth in 2026 amid regulatory and market changes.
Q3 2025 Samsung Life Insurance Co Ltd Earnings Call Transcript
Q3 2025 Samsung Life Insurance Co Ltd Earnings Call Transcript
Samsung Life Insurance Earnings Call Transcript: Q3 2025
New business CSM and net profits grew year-over-year, driven by health product expansion and improved investment yields. RBC ratio strengthened, and the company remains focused on high-margin products, stable CSM growth, and shareholder returns.
Samsung Life Insurance Q3 Profit Rises On Strong Sales Growth
(RTTNews) - Samsung Life Insurance Co., Ltd. (032830.KS) reported Thursday higher profit and sales in its third quarter.
Q1 2025 Samsung Life Insurance Co Ltd Earnings Presentation Transcript
Q1 2025 Samsung Life Insurance Co Ltd Earnings Presentation Transcript
Samsung Life Insurance Earnings Call Transcript: Q2 2025
Net profit rose 1.9% year-on-year to KRW 1.394 trillion in H1 2025, driven by robust health insurance growth and strong CSM performance. KICS ratio improved to 187%, with a focus on maintaining capital adequacy and increasing shareholder returns.
Samsung Life Insurance Earnings Call Transcript: Q1 2025
Q1 2025 net profit rose 2.1% year-over-year to ₩635.3 billion, driven by strong health segment growth and investment gains. K-ICS ratio remains robust at 180%, with a focus on high-margin health products and a progressive move toward a 50% payout ratio.
Samsung Life Insurance Earnings Call Transcript: Q4 2024
Record net profit and strong health product sales drove growth, with a focus on capital soundness and higher dividends. K-ICS ratio is expected to remain robust despite market headwinds, and a 50% payout ratio is targeted within four years.
Samsung Life Insurance Earnings Call Transcript: Q3 2024
Q3 saw robust growth in health product sales, boosting new business CSM and net profit. Solvency ratios are being recalibrated amid regulatory changes, with capital management and dividend policy under review. Strategic focus is shifting toward senior and healthcare business.
Samsung Life Insurance Co Ltd (XKRX:032830) Q2 2024 Earnings Call Transcript Highlights: Strong ...
Samsung Life Insurance Co Ltd (XKRX:032830) Q2 2024 Earnings Call Transcript Highlights: Strong Net Profit Growth and Strategic Adjustments
Q2 2024 Samsung Life Insurance Co Ltd Earnings Call Transcript
Q2 2024 Samsung Life Insurance Co Ltd Earnings Call Transcript
Samsung Life Insurance Earnings Call Transcript: Q2 2024
Net profit surged 40.5% year-on-year in H1 2024, driven by strong insurance and investment results. Health product CSM grew sharply, and the company targets a 50% shareholder payout ratio within 3–4 years, pending regulatory changes.